{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:07:51Z","timestamp":1791824871064,"version":"4.3.4"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T00:00:00Z","timestamp":1579651200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Ba\u015fkent University Research Fund."}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.jgar.2019.09.016","type":"journal-article","created":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T11:45:46Z","timestamp":1569584746000},"page":"334-338","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["In vitro activity of ceftolozane\u2013tazobactam and ceftazidime\u2013avibactam against clinical isolates of meropenem-non-susceptible Pseudomonas aeruginosa: A two-centre study"],"prefix":"10.1016","volume":"20","author":[{"given":"Hasan Cenk","family":"Mirza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvan","family":"Horta\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aylin Altay","family":"Ko\u00e7ak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Hamiyet","family":"Demirkaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Buket","family":"Yayla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aylin \u00dcsk\u00fcdar","family":"G\u00fc\u00e7l\u00fc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Ba\u015fustao\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2019.09.016_bib0005","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.diagmicrobio.2018.01.023","article-title":"Amikacin and cefoperazone\/sulbactam alone or in combination against carbapenem-resistant Pseudomonas aeruginosa","volume":"91","author":"Cai","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2019.09.016_bib0010","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1128\/AAC.05024-14","article-title":"Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013","volume":"59","author":"Sader","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2019.09.016_bib0015","doi-asserted-by":"crossref","first-page":"6407","DOI":"10.1128\/AAC.01282-16","article-title":"Activity of ceftazidime-avibactam against clinical and isogenic laboratory Pseudomonas aeruginosa isolates expressing combinations of most relevant \u03b2-lactam resistance mechanisms","volume":"60","author":"Torrens","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2019.09.016_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0176774","article-title":"Molecular epidemiological survey of bacteremia by multidrug resistant Pseudomonas aeruginosa: the relevance of intrinsic resistance mechanisms","volume":"12","author":"Dantas","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2019.09.016_bib0025","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/jac\/dkg416","article-title":"Dissemination in distinct Brazilian regions of an epidemic carbapenem-resistant Pseudomonas aeruginosa producing SPM metallo-beta-lactamase","volume":"52","author":"Gales","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2019.09.016_bib0030","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00875-17","article-title":"Multicenter evaluation of ceftazidime-avibactam and ceftolozane-tazobactam inhibitory activity against meropenem-nonsusceptible Pseudomonas aeruginosa from blood, respiratory tract, and wounds","volume":"61","author":"Grupper","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2019.09.016_bib0035","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00054-17","article-title":"Antimicrobial effects of \u03b2-lactams on imipenem-resistant ceftazidime-susceptible Pseudomonas aeruginosa","volume":"61","author":"Wi","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2019.09.016_bib0040","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1086\/649021","article-title":"Imipenem resistance in Pseudomonas aeruginosa: emergence, epidemiology, and impact on clinical and economic outcomes","volume":"31","author":"Lautenbach","year":"2010","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.jgar.2019.09.016_bib0045","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1128\/AAC.02969-15","article-title":"Evaluation of the in vitro activity of ceftazidime-avibactam and ceftolozane-tazobactam against meropenem-resistant Pseudomonas aeruginosa isolates","volume":"60","author":"Buehrle","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2019.09.016_bib0050","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01858-17","article-title":"Activity of ceftolozane-tazobactam and ceftazidime-avibactam against beta-lactam-resistant Pseudomonas aeruginosa isolates","volume":"61","author":"Humphries","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2019.09.016_bib0055","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01093-17","article-title":"Verification of ceftazidime-avibactam and ceftolozane-tazobactam susceptibility testing methods against carbapenem-resistant enterobacteriaceae and Pseudomonas aeruginosa","volume":"56","author":"Shields","year":"2018","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2019.09.016_bib0060","series-title":"Avycaz (ceftazidime-avibactam) package insert","author":"FDA","year":"2018"},{"key":"10.1016\/j.jgar.2019.09.016_bib0065","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.jgar.2019.09.016_bib0070","series-title":"Performance standards for antimicrobial susceptibility testing: twenty-eighth informational supplement M100-S28","author":"CLSI","year":"2018"},{"key":"10.1016\/j.jgar.2019.09.016_bib0075","author":"EUCAST"},{"key":"10.1016\/j.jgar.2019.09.016_bib0080","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijid.2017.06.007","article-title":"Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa","volume":"62","author":"Alatoom","year":"2017","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jgar.2019.09.016_bib0085","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02083-16","article-title":"Antimicrobial activity of ceftazidime-avibactam against gram-negative bacteria isolated from patients hospitalized with pneumonia in U.S. medical centers, 2011 to 2015","volume":"61","author":"Sader","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2019.09.016_bib0090","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.bjid.2017.06.008","article-title":"Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013\u20132015)","volume":"21","author":"Pfaller","year":"2017","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.jgar.2019.09.016_bib0095","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1128\/AAC.04238-14","article-title":"Unexpected challenges in treating multidrug-resistant Gram-negative bacteria: resistance to ceftazidime-avibactam in archived isolates of Pseudomonas aeruginosa","volume":"59","author":"Winkler","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2019.09.016_bib0100","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1093\/jac\/dkv004","article-title":"Selection and molecular characterization of ceftazidime\/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC","volume":"70","author":"Lahiri","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2019.09.016_bib0105","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/jac\/dkx424","article-title":"Mechanisms leading to in vivo ceftolozane\/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa","volume":"73","author":"Fraile-Ribot","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2019.09.016_bib0110","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1128\/AAC.02462-13","article-title":"Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC","volume":"58","author":"Cabot","year":"2014","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716519302498?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716519302498?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:56:05Z","timestamp":1761990965000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716519302498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":22,"alternative-id":["S2213716519302498"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2019.09.016","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of ceftolozane\u2013tazobactam and ceftazidime\u2013avibactam against clinical isolates of meropenem-non-susceptible Pseudomonas aeruginosa: A two-centre study","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2019.09.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Society for Antimicrobial Chemotherapy. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}